Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDAC Meeting On Actual-Use Trials Scheduled For September

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs Advisory Committee will convene Sept. 25 to "consider issues related to the analysis and interpretation of consumer behavior studies conducted to support marketing" of OTCs

You may also be interested in...

NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm

Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1

ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley

FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year

Actual Use, Label Comprehension Guidances Slated For 2006

Guidances under development in 2006 reflect FDA's interest in improving the quality of Rx-to-OTC switch submissions

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts